companies developing glp-1 drugs The $100 Billion Weight Loss Drug War Has Officially Started The current range of weight-loss
Description
After a median follow-up of 2 years, the incidence of new or worsening nephropathy in the semaglutide group was lower than that in the placebo group [HR 0.64 (95% CI: 0.460.88, p=0.05)]
For cohort and casecontrol designs, study quality was assessed using the Newcastle-Ottawa Quality Assessment Scale (NOS)
The safety implications are serious
For detailed information about this topic, read our comparison of Ozempic vs compounded semaglutide
SS: Investigation, Methodology, Writing original draft, Software, Formal analysis, Data curation, Resources
